Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advances in the study of bioactivity and structure-function relationship of regulatory peptide AcSDKP

( views:162, downloads:4 )

Author:: No author available

Journal Title:: ACTA PHARMACEUTICA SINICA

Issue:: 8

DOI:: 10.3321/j.issn:0513-4870.2007.08.002

Key Word:: AcSDKP;多肽因子;生物学活性;构效关系

Abstract： AcSDKP是从胎牛骨髓中提取的一种以细胞生长抑制作用为主的多功能生理调控因子,不仅具有抑制造血干细胞生长的生物学功能,对淋巴细胞、肝细胞、肾间质成纤维细胞及心肌成纤维细胞等多种细胞均有增殖抑制作用.同时还能介导血管的生成,对生殖系统也有明显刺激作用,可促进精子生成.本文就AcSDKP的多种生物学活性及最新研究进展作一综述.

Reference

[1]戴国,黄畅,李烨,等.AcSDKP抑制体外培养条件下人骨髓间充质干细胞的增殖[J].2006,(2).
[2]肖慧捷.造血细胞生长抑制因子抑制大鼠肾间质成纤维细胞的生长[J].2001,(2).
[3]杨方,朱曦龄,王丽平,等.抗纤维化短肽N-乙酰基-丝氨酰-天门冬酰-赖氨酰-脯氨酸对大鼠心脏成纤维细胞胶原合成与降解的调节作用[J].2006,(9).
[4]A, Massé,L H, Ramirez,G, Bindoula,etc.The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors.[J].1998,91.
[5]Jean, Boutonnat,Anne-Marie, Faussat,Jean-Pierre, Marie,etc.Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.[J].2005,5.
[6]Smits JF,Roks AJ,Pokharel S,etc.N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts.[J].2002,40(2).
[7]Dammacco F,Ribatti D,Vacca A,etc.Hematopoiesis and angiogenesis: a link between two apparently independent processes.[J].2000,9(1).
[8]J, Thierry,C, Grillon,S, Gaudron,etc.Synthesis and biological evaluation of analogues of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro (AcSDKP), an inhibitor of primitive haematopoietic cell proliferation.[J].2001,7.
[9]Cingolani OH,Liu YH,Rhaleb NE,etc.Reduction of cardiac fibrosis decreases systolic performance without affecting diastolic function in hypertensive rats.[J].2004,43(5).
[10]Christos, Zikos,Evangelia, Livaniou,Leondios, Leondiadis,etc.Comparative evaluation of four trityl-type amidomethyl polystyrene resins in Fmoc solid phase peptide synthesis.[J].2003,9.
[11]Michel, Azizi,Jo?l, Ménard,Séverine, Peyrard,etc.Assessment of patients' and physicians' compliance to an ACE inhibitor treatment based on urinary N-acetyl Ser-Asp-Lys-Pro determination in the Noninsulin-Dependent Diabetes, Hypertension, Microalbuminuria, Proteinuria, Cardiovascular Events, and Ramipril[J].2006,29.
[12]N, Cheviron,A, Rousseau-Plasse,M, Lenfant,etc.Coumarin-Ser-Asp-Lys-Pro-OH, a fluorescent substrate for determination of angiotensin-converting enzyme activity via high-performance liquid chromatography.[J].2000,280(1).
[13]T, Watanabe,G S, Brown,L S, Kelsey,etc.In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation.[J].1996,24.
[14]P K, Wierenga,M K, Brenner,A W, Konings.Enhanced selectivity of hyperthermic purging of human progenitor cells using Goralatide, an inhibitor of cell cycle progression.[J].1998,21(1).
[15]Hakovirta H.,Jegou B.,Stephan JP.,etc.Source, catabolism and role of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro within the testis[J].2000,113(1).
[16]A, Rousseau-Plasse,J, Wdzieczak-Bakala,M, Lenfant,etc.Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.[J].1998,26.
[17]Junot C,Clement G,Wdzieczak Bakala J,etc.Development of an enzyme immunoassay for a stable amidated analog of the hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro.[J].2001,22(1).
[18]Folker E, Franke,Katharina, Pauls,Roman, Metzger,etc.Angiotensin I-converting enzyme and potential substrates in human testis and testicular tumours.[J].2003,111.
[19]Wdzieczak Bakala-J,Riches A,Gaudron S,etc.In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation.[J].1999,17(2).
[20]Ludovic, Waeckel,Jér?me, Bignon,Jian-Miao, Liu,etc.Tetrapeptide AcSDKP induces postischemic neovascularization through monocyte chemoattractant protein-1 signaling.[J].2006,26.
[21]Muraki T,Yoshioka T,Nitta K,etc.Acetyl-seryl-aspartyl-lysyl-proline is a novel natural cell cycle regulator of renal cells.[J].2000,66(15).
[22]Hemerly JP,Smith MC,Caires AC,etc.Effects of palladacycle complex on hematopoietic progenitor cells proliferation in vivo and in vitro and its relation with the inhibitory properties of this compound on the angiotensin-I converting enzyme activity.[J].2004,26(4).
[23]Janina Wyczółkowska,Aurelia Walczak-Drzewiecka,Waldemar Wagner,etc.Thymosin β4 and thymosin β4-derived peptides induce mast cell exocytosis[J].2007,28(4).
[24]Sukeerthi Kumar,Céline Flamant-Robin,Qian Wang,etc.Synthesis of 4-Substituted-3-aminopiperidin-2-ones: Application to the Synthesis of a Conformationally Constrained Tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro[J].2005,70(15).
[25]Wei Qi Huang,Qi Ru Wang.Bone marrow endothelial cells secrete thymosin β4 and AcSDKP[J].2001,29(1).
[26]Carretero OA,Rhaleb NE,Peng H,etc.Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.[J].2001,37(3).
[27]Rhaleb NE,Carretero OA,Yang XP,etc.Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.[J].2004,43(5).
[28]J, Thierry,M P, Papet,N, Saez-Servent,etc.Synthesis and activity of NAcSerAspLysPro analogues on cellular interactions between T-cell and erythrocytes in rosette formation.[J].1990,33.
[29]J E, Chisi,C V, Briscoe,E, Ezan,etc.Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation.[J].2000,109(3).
[30]Rhaleb NE,Carretero OA,Yang F,etc.Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction.[J].2004,43(2).
[31]A, Suzuki,S, Aizawa,S, Araki,etc.Enhanced engraftment of intravenously transplanted hematopoietic stem cells into bone marrow of irradiated mice treated with AcSDKP.[J].1998,26.
[32]Sandrine Gaudron,Marie-Thérèse Adeline,Pierre Potier,etc.NAcSDKP Analogues Resistant to Angiotensin-Converting Enzyme[J].1997,40(24).
[33]Rhaleb NE,Peng H,Brigstock DR,etc.Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.[J].2003,42(6).
[34]Azizi M,Menard J,Ezan E,etc.Angiotensin I-converting enzyme and metabolism of the haematological Peptide N-acetyl-seryl-aspartyl-lysyl-proline.[J].2001,28(12).
[35].RXP 407, a Selective Inhibitor of the N-Domain of Angiotensin I-Converting Enzyme, Blocks in Vivo the Degradation of Hemoregulatory Peptide Acetyl-Ser-Asp-Lys-Pro with No Effect on Angiotensin I Hydrolysis[J].2001,297(2).
[36]Chauvet MT,Michaud A,Corvol P.N-domain selectivity of angiotensin I-converting enzyme as assessed by structure-function studies of its highly selective substrate, N-acetyl-seryl-aspartyl-lysyl-proline.[J].1999,57(6).
[37]Gonzales MF,Michaud A,Corvol P,etc.In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis.[J].1999,289(3).
[38]Ribatti, Domenico,Vacca, Angelo,De Falco, Giuseppe,etc.Role of Hematopoietic Growth Factors in Angiogenesis.[J].2001,106(4).
[39]Ozerol E,Ewel C,Jackson JD,etc.Activity of acetyl-Ser-Asp-Lys-Pro (AcSDKP) on human hematopoietic progenitor cells in short-term and long-term bone marrow cultures.[J].2000,9(4).